
Bringing innovative medicines
to China
from around the globe
OUR VISION
To improve patient care by partnering with innovative companies from around the world to accelerate drug development and bring new medicines to China

Build a World Leading Company

Accelerate Clinical Development

Transform Medical Practice
OUR STORY


Blossom Bioscience was co-founded and incubated by Cormorant Asset Management and Hansoh Pharmaceutical Group. A $72M Series A financing was completed in June 2021 co-led by Cormorant and Hansoh.
Blossom Bioscience has robust capabilities and capital to advance innovative medicines through clinical development. Our partnership with Hansoh Pharma provides development capabilities and expertise in China to bring novel treatments to patients in need. Our close relationship with Cormorant Asset Management enhances licensing activities with access to its extensive global biotech network.